High-dose leucovorin, fluorouracil and oral dipyridamole in the treatment of advanced colorectal cancer.
Fifty-five patients with advanced colorectal cancer were treated with the combination of leucovorin (LV), fluorouracil (FU) and dipyridamole (DP). Two (4%) patients achieved a clinical complete remission, 4 (7%) a partial remission, 24 (44%) had stable disease while 25 (45%) patients progressed during the chemotherapy period. Median survival was 47 weeks and median time to progression 19.5 weeks. Major toxicities included diarrhea (66%), leukopenia (45%), anemia (50%) and nausea/vomiting (44%). In conclusion, the addition of oral DP does not appear to improve the efficacy of the standard LV/FU regimen in patients with advanced colorectal cancer.
Fountzilas
G
G
AHEPA University Hospital, Thessaloniki, Greece.
Zisiadis
A
A
Kosmidis
P
P
Basdanis
G
G
Makrantonakis
P
P
Paspatis
A
A
Tsavdaridis
D
D
Tsavaris
N
N
Aletras
O
O
Tourkantonis
A
A
D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004176:Dipyridamole / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012004:Rectal Neoplasms / Q000188:drug therapy*
D004176:Dipyridamole; D002955:Leucovorin; D005472:Fluorouracil